CPA
ITOS

Capital Performance Advisors’s iTeos Therapeutics ITOS Stock Holding History

Capital Performance Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30
Closed -$306 – 1397
2024
Q3 		$306 Buy
+30
New +$458 ﹤0.01% 2455

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Capital Performance Advisors's ITOS Position: Q4 2024 in Review

Capital Performance Advisors sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 30 shares — an estimated $306 sold.

Capital Performance Advisors first reported a position in ITOS in Q3 2024 and held it in 1 quarter. The position peaked at $306 in Q3 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Capital Performance Advisors reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 30 iTeos Therapeutics shares in Q4 2024, an estimated $306.
  • Capital Performance Advisors first reported a position in iTeos Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's iTeos Therapeutics position peaked at $306 in Q3 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.